Instytut Genetyki I Immunologii Genim Sp. z o.o.

Lublin 9 trials 5 recruiting

9 Registered trials

5 Currently recruiting

Organisation

Instytut Genetyki I Immunologii Genim Sp. z o.o.

Location

Lublin, Poland

Identifier

ORG-100043518

Address

Ul. Filaretow 27/2, 20-609, Poland

Departments

N/A
NA
Thoracic Oncology

Clinical trials at this site (9)

Search interface

Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Ad… Pending

2025-521221-32-00 Advanced or Metastatic Non-Small Cell Lung Cancer 5
A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C… Recruiting

2024-517968-36-00 non-small cell lung cancer 5 2025-07-08
A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po… Recruiting

2023-505604-32-00 Non small cell lung cancer (NSCLC) 5 2024-01-24
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N… Recruiting

2023-503920-14-00 Non-Small Cell Lung Cancer (NSCLC) 5 2024-01-02
A Study to Learn About the Study Medicine Called PF-08046054/SGNPDL1V Versus Docetaxel in Adult Participants with Previously-treated Program… Recruiting

2025-521281-97-00 Non-Small Cell Lung Cancer (NSCLC) 5 2025-12-02
Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting

2024-518154-16-00 non-small cell lung cancer 5 2025-08-27
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer (PolyDamas) Ended

2022-501452-29-00 Metastatic Non-small Cell Lung Cancer 9 2024-08-28
A Clinical Study to Evaluate the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small … Ended

2023-508256-19-00 Unresectable Metastatic Non-small Cell Lung Cancer 9 2024-07-15
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16